Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Areti Kourti has a total of 72 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Oxidative Stress and Its Molecular Effectors in Uterine Smooth Muscle Tumors: Bridging Epigenetic Regulation and Glycoprotein Biomarkers

    by Areti Kourti, Paraskevi Karioti, Foteini Chouliara, Elisavet Georgiou, Kali Makedou, Ioannis Kalogiannidis

    Background: Uterine smooth muscle tumors present a diverse clinical spectrum, ranging from ubiquitous benign leiomyomas to highly lethal uterine leiomyosarcomas (uLMSs). The preoperative differentiation of these entities, alongside the intermediate smooth muscle tumors of uncertain malignant potential (STUMP), remains an unresolved clinical challenge. Methods: This comprehensive review synthesizes the current literature on the pathogenesis of uterine smooth muscle tumors, focusing on the role of oxidative stress and its downstream molecular effectors. We evaluate the interplay between oxidative stress markers, epigenetic regulation via microRNAs (miRNAs), and circulating glycoproteins. Results: Increased oxidative stress is a hallmark associated with uLMS, characterized by altered antioxidant enzyme activity and elevated lipid peroxidation products such as malondialdehyde (MDA). This oxidative burden is associated with DNA damage and profound genomic instability, participating in the evolution of the malignant phenotype. Concurrently, the stressed tumor microenvironment exhibits significant epigenetic deregulation. Tumor-suppressive miRNAs (e.g., the miR-29 and miR-200 families) are downregulated, while oncogenic miRNAs (e.g., miR-21) are upregulated, promoting survival and proliferation pathways. Furthermore, galectin-1, a glycoprotein responsive to microenvironmental stress, is elevated in the serum of uLMS and STUMP patients, demonstrating high specificity in investigated cohorts, though limited sensitivity (47%), whereas mucin-1 (MUC1) shows no significant diagnostic utility. Conclusions: Oxidative stress is strongly associated with the genomic instability and molecular derangements observed in uterine sarcomas. Integrating oxidative stress indicators with specific miRNA signatures and galectin-1 levels could potentially yield robust, non-invasive diagnostic panels. However, prospective validation in large, independent cohorts is strictly required before these markers can be implemented to improve preoperative risk stratification and guide targeted therapeutic interventions.

  • Open Access

    Diagnostic Performance of Galectin-1 and Mucin-1 in Uterine Tumors: A Case–Control Study

    by Paraskevi Karioti, Aikaterini Sidera, Ioannis Tsakiridis, Areti Kourti, Georgios Karavas, Themistoklis Dagklis, Apostolos Mamopoulos, Apostolos Athanasiadis, Kali Makedou, Ioannis Kalogiannidis

    Background and Objectives: Uterine leiomyomas are common benign tumors, whereas uterine sarcomas are rare but aggressive malignancies. Preoperative differentiation among leiomyoma, smooth muscle tumor of uncertain malignant potential (STUMP), and uterine sarcoma remains a major clinical challenge, with diagnosis often established only after histopathological evaluation. The identification of reliable circulating biomarkers could improve preoperative risk stratification and guide surgical decision-making. This study aimed to evaluate the usefulness of galectin-1 and mucin-1 in the diagnosis of uterine tumors. Materials and methods: This prospective, single-center case–control study was conducted at the Third Department of Obstetrics & Gynecology, School of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, Greece, between 2013 and 2024. Serum galectin-1 and mucin-1 levels were measured preoperatively using ELISA and electrochemiluminescence immunoassay (ECLIA), respectively. Group comparisons were performed using non-parametric tests. Diagnostic performance was evaluated using receiver operating characteristic (ROC) curve analysis. Multivariable logistic regression was used to assess independent associations with sarcomas/STUMP status. Results: The study population comprised 156 women (49 healthy controls, 90 patients with uterine myomas, 8 with STUMP and 9 patients with uterine sarcomas) treated during the study period. Galectin-1 differed significantly across the four histological groups (p < 0.001), with higher concentrations in uterine sarcoma than in healthy controls (p < 0.001) and leiomyoma (p = 0.002). MUC1 also differed overall (p = 0.031), with higher concentrations in uterine sarcoma than in leiomyoma (adjusted p = 0.031). In the primary leiomyoma versus sarcoma/STUMP ROC analysis, galectin-1 showed modest discrimination (AUC 0.693, 95% CI 0.559–0.826), while MUC1 showed weaker discrimination (AUC 0.618, 95% CI 0.468–0.768). Conclusions: Serum galectin-1 may have potential as an adjunctive biomarker in the preoperative assessment of uterine tumors, but its modest discrimination and unstable cutoff-dependent performance may preclude its use as a standalone diagnostic test. MUC1 showed limited diagnostic utility in the primary clinical comparison. Given the clinical implications of misdiagnosis, particularly regarding surgical management, further validation in larger cohorts and multimarker approaches are warranted.


  • Open Access

    A Review of Proteomic Studies in Uterine Leiomyosarcoma: Biomarkers, Pathways, and Clinical Potential

    by Areti Kourti, Andigoni Malousi, Konstantina Psatha, Ioannis Kalogiannidis, Michalis Aivaliotis, Elisavet Georgiou

    Uterine leiomyosarcoma (uLMS) is a rare but highly aggressive mesenchymal malignancy of smooth-muscle origin that represents a significant therapeutic challenge due to its poor prognosis and limited treatment options. Despite advances in molecular characterization, diagnosis remains difficult, and systemic therapies have shown limited success, contributing to a high recurrence rate and poor survival. Recent proteomic investigations have provided new insights into uLMS biology by exploring the global protein expression patterns that define malignant transformation and progression. Using high-resolution mass spectrometry (MS)-based techniques, quantitative proteomics, and integrated multi-omics approaches, researchers have begun to identify dysregulated proteins, signaling pathways, and post-translational modifications (PTMs) linked to tumor metabolism, extracellular matrix (ECM) remodeling, cell-cycle regulation, and chemoresistance. These studies have also uncovered candidate biomarkers that may improve the discrimination of uLMS from benign leiomyoma and have proposed novel therapeutic targets associated with metabolic reprogramming, kinase activation and tumor microenvironment (TME) modulation. This review summarizes recent advancements in uLMS proteomics, discusses their methodological underpinnings, highlights key molecular mechanisms and biomarkers, and explores their translational potential. Finally, we outline current limitations and future directions toward clinical implementation of proteomic findings in precision oncology for uLMS patients.

  • Open Access

    Oxidative Stress and Its Molecular Effectors in Uterine Smooth Muscle Tumors: Bridging Epigenetic Regulation and Glycoprotein Biomarkers

    by Areti Kourti, Paraskevi Karioti, Foteini Chouliara, Elisavet Georgiou, Kali Makedou, Ioannis Kalogiannidis

    Background: Uterine smooth muscle tumors present a diverse clinical spectrum, ranging from ubiquitous benign leiomyomas to highly lethal uterine leiomyosarcomas (uLMS). The preoperative differentiation of these entities, alongside the intermediate smooth muscle tumors of uncertain malignant potential (STUMP), remains an unresolved clinical challenge. Methods: This comprehensive review synthesizes the current literature on the pathogenesis of uterine smooth muscle tumors, strictly focusing on the role of oxidative stress and its downstream molecular effectors. We evaluate the interplay between oxidative stress markers, epigenetic regulation via microRNAs (miRNAs), and circulating glycoproteins. Results: Increased oxidative stress is a hallmark of uLMS, characterized by altered antioxidant enzyme activity and elevated lipid peroxidation products such as malondialdehyde (MDA). This oxidative burden drives DNA damage and profound genomic instability, facilitating the evolution of the malignant phenotype. Concurrently, the stressed tumor microenvironment exhibits significant epigenetic deregulation. Tumor-suppressive miRNAs (e.g., the miR-29 and miR-200 families) are downregulated, while oncogenic miRNAs (e.g., miR-21) are upregulated, hyperactivating survival and proliferation pathways. Furthermore, galectin-1, a glycoprotein responsive to microenvironmental stress, is significantly elevated in the serum of uLMS and STUMP patients, demonstrating a high specificity (100%) for malignancy, whereas mucin-1 (MUC1) shows no significant diagnostic utility. Conclusions: Oxidative stress serves as a central catalyst for the genomic instability and molecular derangements observed in uterine sarcomas. Integrating oxidative stress indicators with specific miRNA signatures and galectin-1 levels could yield robust, non-invasive diagnostic panels, ultimately improving preoperative risk stratification and guiding targeted therapeutic interventions.

  • Open Access

    A Review of Proteomic Studies in Uterine Leiomyosarcoma: Biomarkers, Pathways, and Clinical Potential

    by Areti Kourti, Andigoni Malousi, Konstantina Psatha, Ioannis Kalogiannidis, Michalis Aivaliotis, Elisavet Georgiou

    Uterine leiomyosarcoma (uLMS) is a rare but highly aggressive mesenchymal malig-nancy of smooth muscle origin that represents a significant therapeutic challenge due to its poor prognosis and limited treatment options. Despite advances in molecular charac-terization, diagnosis remains difficult, and systemic therapies have shown limited success, contributing to a high recurrence rate and poor survival. Recent proteomic investigations have provided new insights into uLMS biology by exploring the global protein expres-sion patterns that define malignant transformation and progression. Using high-resolution mass spectrometry (MS)-based techniques, quantitative proteomics, and integrated multi-omics approaches, researchers have begun to identify dysregulated proteins, signaling pathways, and post-translational modifications (PTMs) linked to tumor metabolism, extracellular matrix (ECM) remodeling, cell-cycle regulation, and chemo-resistance. These studies have also uncovered candidate biomarkers that may improve the discrimination of uLMS from benign leiomyoma and have proposed novel therapeutic targets associated with metabolic reprogramming, kinase activation and tumor micro-environment (TME) modulation. This review summarizes recent advancements in uLMS proteomics, discusses their methodological underpinnings, highlights key molecular mechanisms and biomarkers, and explores their translational potential. Finally, we outline current limitations and future directions toward clinical implementation of pro-teomic findings in precision oncology for uLMS patients.

  • Open Access

    GDF-15: Can It Be Used as a Biomarker in Acute Cerebrovascular Incidents?

    by Areti Kourti, Eirini Keskilidou, Alexandra Skoura, Paraskevi Karalazou, Katerina Thisiadou, Kali Makedou

    Background/Objectives: Growth differentiation factor-15 (GDF-15) is a protein that belongs to the transforming growth factor beta superfamily and has been found elevated in cases of organ injury such as liver, kidney, heart, and lung, as well as cardiovascular diseases and cancer. Soluble urokinase plasminogen activator receptor (suPAR) is a protein which is expressed mainly on immune cells and endothelial and smooth muscle cells, and is a marker of severity and intensity of inflammation in acute and chronic diseases. The aim of the present study was to compare GDF-15 serum levels between patients with acute cerebrovascular incidents and healthy controls and to investigate the possible correlation of GDF-15 serum levels and inflammatory markers, such as serum C-reactive protein (CRP) and plasma suPAR, in the above-mentioned groups. Methods: This is a retrospective study. Thirty-one patients were included in the study, with a mean age ± SD of 67 ± 13 years, compared to 18 age-matched healthy controls. Results: In the patient group a statistically significant positive correlation of serum levels of GDF15 values with suPAR and CRP emerged (rs = 0.516, p = 0.003) and (rs = 0.409, p = 0.022), respectively, and no significant correlation was found in the group of controls (rs = 0.271, p = 0.277) and (rs = 0.423, p = 0.080), respectively. Conclusions: These findings support the role of inflammation as a key underlying mechanism in acute cerebrovascular injury and suggest that GDF-15 may serve as a valuable adjunct biomarker for assessing disease severity and inflammatory burden.

  • Open Access

    Integrated Inflammatory Biomarker Profiling Differentiates Degrees of Body Mass Index Beyond Intestinal Barrier-Related Markers

    by Theocharis Koufakis, Areti Kourti, Katerina Thsiadou, Paraskevi Karalazou, Ioannis Georgiadis, Dimitrios Patoulias, Djordje S. Popovic, Giuseppe Maltese, Alexander Kokkinos, Kalliopi Kotsa, et al.

    Obesity is characterized by low-grade systemic inflammation and alterations in gut-related immune pathways that may contribute to metabolic dysfunction. Composite biomarker indices may better capture these complex processes than individual markers, although their performance may differ across biological domains. In this cross-sectional study, 88 adults without diabetes or infection were categorized as BMI < 25 kg/m2 (n = 20), BMI 25–29.9 kg/m2 (n = 34), or BMI ≥ 30 kg/m2 (n = 34). Circulating biomarkers reflecting systemic inflammation (high-sensitivity C-reactive protein, ferritin, interleukin-6, presepsin) and intestinal barrier-related activity (β-defensin-2, regenerating islet-derived protein 3 alpha) were measured and subsequently combined into two composite indices: the Inflammatory Load Index, derived from inflammatory markers, and the Barrier Activation Index, derived from barrier-related markers. Group differences were assessed using analysis of variance with post hoc testing. Additional analyses included effect size estimation, receiver operating characteristic (ROC) analysis, and logistic regression. Individual biomarkers showed limited differences across BMI categories. The Inflammatory Load Index differed significantly across BMI categories (p = 0.040), with higher values observed in individuals with BMI ≥ 30 kg/m2 compared with those with BMI 25–29.9 kg/m2 (p = 0.032; Cohen’s d = 0.80), while the Barrier Activation Index did not differ (p = 0.257). In ROC analysis, the Inflammatory Load Index discriminated BMI ≥ 30 kg/m2 with an area under the curve of 0.720 (95% confidence interval 0.576–0.851), yielding 77.8% sensitivity and 67.7% specificity. Each one standard deviation increase in the index was associated with higher odds of obesity (odds ratio 2.34, 95% confidence interval 1.22–4.49; p = 0.011). In conclusion, a composite inflammatory biomarker index, but not a barrier-related index, differentiates degrees of BMI in individuals without diabetes. These findings support integrated biomarker approaches for reflecting obesity-related biological burden beyond single markers. However, these observations are based on cross-sectional data and do not imply causality.

  • Open Access

    The Impact of Osteopontin and Galectin-7 on the Preoperative Diagnosis of Ovarian Tumors: A Case–Control Study

    by Foteini Chouliara, Aikaterini Sidera, Ioannis Tsakiridis, Areti Kourti, Georgios Michos, Evangelos Papanikolaou, Themistoklis Dagklis, Apostolos Mamopoulos, Kali Makedou, Ioannis Kalogiannidis

    Background/Objectives: Accurate preoperative discrimination between women with ovarian pathology and healthy controls, as well as between benign and malignant ovarian tumors, remains challenging. This study aimed to evaluate the usefulness of osteopontin and galectin-7 on the diagnosis of ovarian tumors. Methods: This prospective single-center case–control study was conducted at the Third Department of Obstetrics & Gynecology, School of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, Greece, between 2018 and 2024. Preoperative serum levels of osteopontin, galectin-7, and established tumor markers (CA-125, CA19-9, CA15-3, CEA, AFP) were analyzed. Biomarker distributions were compared using non-parametric tests. Associations with clinical variables were explored using correlation analyses. Logistic regression and receiver operating characteristic (ROC) curve analyses were performed to assess diagnostic performance. Results: The study population included 116 women: 52 healthy controls, 45 patients with benign ovarian tumors, and 19 patients with malignant ovarian tumors. Serum osteopontin and galectin-7 levels did not differ significantly between control and study group (p = 0.562 and p = 0.138, respectively), nor between benign and malignant tumors (p = 0.784 and p = 0.140, respectively). Osteopontin showed no discriminatory ability (AUC = 0.47), while galectin-7 demonstrated weak discrimination (AUC = 0.63). A combined model yielded modest improvement (AUC = 0.69), remaining below clinically meaningful thresholds. CA-125 was the only biomarker significantly associated with malignancy (OR = 1.03, p = 0.038). Galectin-7 levels were higher in premenopausal women and inversely correlated with age, suggesting demographic rather than malignant influence. Conclusions: Despite strong biological relevance, circulating osteopontin and galectin-7 did not provide meaningful diagnostic discrimination between women with ovarian pathology and healthy controls or between benign and malignant ovarian tumors. CA-125 remained the most informative serum marker in this setting. Future efforts should focus on multi-marker strategies integrated with imaging and clinical assessment.

  • Open Access

    Proteomic Analysis in Search of New Biomarkers of Immune Thrombocytopenia (ITP)—A Review of Current Data

    by Anastasia Boura-Theodorou, Konstantina Psatha, Stefania Maniatsi, Areti Kourti, Georgia Kaiafa, Michalis Aivaliotis, Kali Makedou

    Immune thrombocytopenia (ITP) is a hematological disorder commonly found in individuals of any gender, race, or age. Patients with ITP will present with thrombocytopenia either in a primary form or because of an infection or a dysfunction in the immune system. The severity of ITP is linked to diminished production of platelets due to the blockage of production in the bone marrow niche and increased destruction of platelets, which confirms the diagnosis of the disorder. The investigation of the pathogenesis of ITP is of critical importance as it can give an important indication of the state of the patient, guiding us through risk assessment and treatment. Proteomics can provide tools to explore the protein profile of ITP. In this review, we aimed to uncover different biomarkers, both diagnostic and prognostic, that have been investigated with proteomic methodologies and that might help in understanding the pathogenesis of ITP and providing personalized treatment to patients. Several differentially abundant proteins were identified, including haptoglobin isoforms, heat shock proteins (HSPA6, HSPA8), integrin β3 (ITGB3), 14-3-3 protein eta (YWHAH), vitamin D-binding protein, fibrinogen chains, MYH9, and FETUB, which are involved in key signaling pathways, such as PI3K/akt, TNF-a, and mTOR, and they demonstrate potential as diagnostic and prognostic biomarkers. Collectively, current data support the value of proteomics for uncovering the molecular landscape of ITP and guiding the development of precision diagnostics and personalized therapeutic strategies.


  • Open Access

    Comparative measurement of plasma soluble urokinase plasminogen activator receptor using a point-of-care device and a clinical analyzer in stroke patients

    by Areti Kourti, Eirini Keskilidou, Alexandra Skoura, Athanasia Samara, Paraskevi Thanou, Paraskevi Karalazou, Katerina Thisiadou, Kali Makedou

    Background: Soluble urokinase plasminogen activator receptor (suPAR) reflects immune activation and chronic inflammatory responses and has been proposed as a prognostic biomarker in several acute conditions. Objectives: This study aims to evaluate the clinical performance of two analytical methods for plasma suPAR determination in patients with stroke: a point-of-care (POC) lateral-flow assay and an automated particle-enriched turbidimetric immunoassay performed on a biochemistry analyzer. Methods: Plasma samples from 27 patients with stroke and 14 age-matched healthy controls were analyzed with both methods. suPAR concentrations were significantly higher in stroke patients compared with controls for both assays. Results: A statistically significant difference between POC and analyzer measurements was observed only within the stroke group (p=0.024), and a strong positive correlation between the two methods was identified (r = 0.745, p<0.001). Receiver operating characteristic analysis demonstrated higher sensitivity for the POC method (96%) compared with the analyzer (82%), while the specificity was identical (57%). Conclusion: These findings suggest that suPAR measurement using a rapid POC platform provides reliable results and may support early risk stratification in patients with stroke in emergency department settings.